Disc Medicine, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Disc Medicine, Inc. (IRON) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$6.96 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2022-11-10
- Disc Medicine, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2022-09-30 was -$1.58M, a 192.73% decline year-over-year.
- Disc Medicine, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2022-06-30 was -$1.51M, a 734.03% decline year-over-year.
- Disc Medicine, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2022-03-31 was -$3.87M.
- Disc Medicine, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2021-12-31 was $135.00K.
- Disc Medicine, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2021 was $1.73M, a 71773.70% increase from fiscal 2020.
- Disc Medicine, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2020 was $2.41K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$3.09M derived: sum of 2 quarters · filed 2022-11-10 | -$6.96M 10-Q · filed 2022-11-10 | -$6.82M derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | -$1.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$5.38M 10-Q · filed 2022-08-11 | -$5.24M derived: sum of 3 quarters · filed 2022-08-11 | -$3.54M derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-03-31 | -$3.87M 10-Q · filed 2022-05-06 | -$3.73M derived: sum of 2 quarters · filed 2022-05-06 | -$2.03M derived: sum of 3 quarters · filed 2022-11-10 | -$1.79M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-12-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.84M derived: sum of 2 quarters · filed 2022-11-10 | $2.08M derived: sum of 3 quarters · filed 2022-11-10 | $1.73M 10-K · filed 2022-03-10 |
| 2021-09-30 | $1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.94M derived: sum of 2 quarters · filed 2022-11-10 | $1.59M 10-Q · filed 2022-11-10 | $1.39M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $238.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$110.00K 10-Q · filed 2022-08-11 | -$312.59K derived: sum of 3 quarters · filed 2022-08-11 | $449.41K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$348.00K 10-Q · filed 2022-05-06 | -$550.59K derived: sum of 2 quarters · filed 2022-05-06 | $211.41K derived: sum of 3 quarters · filed 2022-05-06 | $885.41K derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | -$202.59K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $559.41K derived: sum of 2 quarters · filed 2022-03-10 | $1.23M derived: sum of 3 quarters · filed 2022-03-10 | $2.41K 10-K · filed 2022-03-10 |
| 2020-09-30 | $762.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $1.44M derived: sum of 2 quarters · filed 2021-11-15 | $205.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $674.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$557.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$1.23M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |